Add "the" Israeli population study on the efficacy of Pfizer/BNT

Belated addition, courtesy de-facto
ljl-covid · Mar 10, 2021 · 4fb4015 · 4fb4015
1 parent 5fae9ba
commit 4fb4015
Showing 1 changed file with 1 addition and 1 deletion.
diff --git a/README.md b/README.md
@@ -303,7 +303,6 @@ Note that the WHO will generally be unable to make statements that their more pr
 * [FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system](https://www.medrxiv.org/content/10.1101/2021.02.15.21251623v2) is a preprint that analyzes more than 60000 individuals at Mayo Clinic, dividing them into a vaccinated cohort (with Pfizer/BioNTech or Moderna) and an unvaccinated one, and retrospectively concluding there was 88.7% efficacy in preventing infection, i.e. a positive RT-PCR test at all, and hence likely also contagiousness, as opposed to just symptomatic cases, which was the benchmark of most of the vaccine trials
 * [Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00528-6/fulltext#coronavirus-linkback-header) tries to make sense of the confusing dosing issues with the Oxford/Astrazeneca (ChAdOx1) vaccine, and provides some tentative evidence in favor of the UK choice of delaying the booster shot to 12 weeks after the initial shot
 
-
 #### Moderna (mRNA-1273)
 
 * [Moderna’s Covid-19 vaccine is strongly effective, early look at data show](https://www.statnews.com/2020/11/16/modernas-covid-19-vaccine-is-strongly-effective-early-look-at-data-show/), with more than 94% efficacy and severe COVID-19 cases only in the control arm, at an interim point of the [COVE trial](https://www.modernatx.com/cove-study), as covered by an article on StatNews
@@ -323,6 +322,7 @@ Note that the WHO will generally be unable to make statements that their more pr
 * [Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants](https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-initiate-study-part-broad-development-plan) as announced in a BioNTech press release, where the company reveals it plans to study the effects of a third booster shots of 30µg of the original vaccine, as well as ongoing discussions with regulatory agencies about potential approval of vaccines specific to B.1.351 (South African) or other variants
 * [Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of ‘real-world’ vaccination outcomes from Israel](https://www.medrxiv.org/content/10.1101/2021.02.01.21250957v1.full)
 * [Pfizer’s vaccine appears to reduce coronavirus transmission](https://www.sciencenews.org/article/coronavirus-covid-19-pfizer-vaccine-may-reduce-transmission) as evidenced by a couple of studies estimating lower viral load in vaccinated people
+* [BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting](https://www.nejm.org/doi/full/10.1056/NEJMoa2101765) in Israel show that in a large number people vaccinated with Pfizer/BioNTech, matched up against unvaccinated individuals, after taking the second shot, efficacy was 94% for symptomatic COVID-19, 92% for "documented infection" (positive RT-PCR, with potentially unclear knowledge of who sought a test), 92% for severe disease, and 87% for hospitalization
 
 #### Oxford-AstraZeneca (AZD 1222 or ChAdOx1)